PanGIA Biotech Announces Upcoming ASCO 2025 Poster Presentation of Collaborative Research

DELRAY BEACH, Fla.--(BUSINESS WIRE)--PanGIA Biotech, a company advancing urine-based, AI-driven diagnostics for early cancer detection, today announced that an abstract co-authored by researchers from PanGIA Biotech, Entopsis Inc., and Genetics Institute of America has been accepted for presentation at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place May 30–June 3, 2025, in Chicago, Illinois.

Development and validation of an AI-enabled prediction of prostate cancer (PCa) using urine-based liquid biopsy (Abstract #3080) has been accepted for presentation in the poster session titled Developmental Therapeutics—Molecularly Targeted Agents and

Share

The abstract, titled Development and validation of an AI-enabled prediction of prostate cancer (PCa) using urine-based liquid biopsy (Abstract #3080), has been accepted for presentation in the poster session titled Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology.

The presentation highlights collaborative research contributing to PanGIA’s AI-driven, urine-based diagnostic platform. The work integrates biomolecular pattern analysis and machine learning to support the development of scalable, non-invasive solutions in cancer care.

ASCO 2025 Presentation Details

• Date: June 2, 2025
• Time: 1:30 – 4:30 p.m. CDT
• Location: McCormick Place, Chicago, IL

“This presentation reflects our focus on developing non-invasive, scalable diagnostics rooted in the promise of liquid biopsy innovation,” said Holly Magliochetti, CEO of PanGIA Biotech. “We remain committed to advancing technologies that may support earlier cancer detection and improve access to care globally.”

Co-authors on the abstract include researchers from PanGIA Biotech, Entopsis Inc., and the Genetics Institute of America.

About PanGIA Biotech

PanGIA Biotech develops AI-integrated liquid biopsy technology designed for global scalability. The PanGIA® platform is a transformative solution for detecting, monitoring, and managing diseases, including cancers as early as Stage 1. Powered by machine learning, this urine-based platform profiles biomolecular patterns to deliver accurate diagnostic insights. PanGIA’s technology is grounded in peer-reviewed research and R&D success, supported by patents to the company for global diagnostic development. With a steadfast commitment to research and innovation, PanGIA’s vision is to revolutionize disease detection and improve healthcare worldwide. For more information, visit www.PanGIABiotech.com.